172 related articles for article (PubMed ID: 27418139)
1. Cucurbitacin B exerts anti-cancer activities in human multiple myeloma cells in vitro and in vivo by modulating multiple cellular pathways.
Yang T; Liu J; Yang M; Huang N; Zhong Y; Zeng T; Wei R; Wu Z; Xiao C; Cao X; Li M; Li L; Han B; Yu X; Li H; Zou Q
Oncotarget; 2017 Jan; 8(4):5800-5813. PubMed ID: 27418139
[TBL] [Abstract][Full Text] [Related]
2. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer.
Zhang H; Zhao B; Wei H; Zeng H; Sheng D; Zhang Y
J Ethnopharmacol; 2022 Apr; 287():114915. PubMed ID: 34954267
[TBL] [Abstract][Full Text] [Related]
3. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets.
Kausar H; Munagala R; Bansal SS; Aqil F; Vadhanam MV; Gupta RC
Cancer Lett; 2013 May; 332(1):35-45. PubMed ID: 23340170
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling.
Zhang M; Sun C; Shan X; Yang X; Li-Ling J; Deng Y
Pancreas; 2010 Aug; 39(6):923-9. PubMed ID: 20182390
[TBL] [Abstract][Full Text] [Related]
5. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
Ueno M; Kariya R; Sittithumcharee G; Okada S
Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
[TBL] [Abstract][Full Text] [Related]
6. Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis.
Sinha S; Khan S; Shukla S; Lakra AD; Kumar S; Das G; Maurya R; Meeran SM
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):41-56. PubMed ID: 27210504
[TBL] [Abstract][Full Text] [Related]
7. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
8. Cucurbitacin B regulates lung cancer cell proliferation and apoptosis
Liu JH; Li C; Cao L; Zhang CH; Zhang ZH
Pharm Biol; 2022 Dec; 60(1):154-162. PubMed ID: 34967707
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis.
Yuan R; Zhao W; Wang QQ; He J; Han S; Gao H; Feng Y; Yang S
Pharmacol Res; 2021 Aug; 170():105748. PubMed ID: 34217831
[TBL] [Abstract][Full Text] [Related]
10. Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity.
Xu J; Chen Y; Yang R; Zhou T; Ke W; Si Y; Yang S; Zhang T; Liu X; Zhang L; Xiang K; Guo Y; Liu Y
Arch Biochem Biophys; 2020 May; 684():108314. PubMed ID: 32088220
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of STAT3 signaling pathway by ursolic acid suppresses growth of hepatocellular carcinoma.
Liu T; Ma H; Shi W; Duan J; Wang Y; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Int J Oncol; 2017 Aug; 51(2):555-562. PubMed ID: 28714512
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.
Sun Y; Zhang J; Zhou J; Huang Z; Hu H; Qiao M; Zhao X; Chen D
Eur J Pharmacol; 2015 Dec; 768():28-40. PubMed ID: 26452516
[TBL] [Abstract][Full Text] [Related]
13. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.
Yang LJ; Tang Q; Wu J; Chen Y; Zheng F; Dai Z; Hann SS
J Exp Clin Cancer Res; 2016 Mar; 35():59. PubMed ID: 27036874
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin B exhibits antitumor effects on CD133+ HepG2 liver cancer stem cells by inhibiting JAK2/STAT3 signaling pathway.
Wang X; Bai Y; Yan X; Li J; Lin B; Dai L; Xu C; Li H; Li D; Yang T; Zhang T
Anticancer Drugs; 2021 Jun; 32(5):548-557. PubMed ID: 33675610
[TBL] [Abstract][Full Text] [Related]
15. Induction of ferroptosis in human nasopharyngeal cancer cells by cucurbitacin B: molecular mechanism and therapeutic potential.
Huang S; Cao B; Zhang J; Feng Y; Wang L; Chen X; Su H; Liao S; Liu J; Yan J; Liang B
Cell Death Dis; 2021 Mar; 12(3):237. PubMed ID: 33664249
[TBL] [Abstract][Full Text] [Related]
16. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
[TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells.
Zhang Y; Ouyang D; Xu L; Ji Y; Zha Q; Cai J; He X
Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):556-67. PubMed ID: 21642275
[TBL] [Abstract][Full Text] [Related]
18. Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.
Jin ZQ; Hao J; Yang X; He JH; Liang J; Yuan JW; Mao Y; Liu D; Cao R; Wu XZ; Li X; Chen D
Oncol Rep; 2018 Oct; 40(4):2127-2136. PubMed ID: 30106443
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin.
Liu T; Peng H; Zhang M; Deng Y; Wu Z
Eur J Pharmacol; 2010 Sep; 641(1):15-22. PubMed ID: 20483353
[TBL] [Abstract][Full Text] [Related]
20. Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Mazzera L; Abeltino M; Lombardi G; Cantoni AM; Ria R; Ricca M; Saltarella I; Naponelli V; Rizzi FMA; Perris R; Corradi A; Vacca A; Bonati A; Lunghi P
Haematologica; 2019 Dec; 104(12):2465-2481. PubMed ID: 30948493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
